Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinco Pharmaceutical HoldingsHKSE:06833 -0.60%44 Dividend Yield % is 1.02% as of Aug. 28, 2026, which is 39% below its 10-year median of 1.67. GuruFocus rates HKSE:06833 with a GF Score™ of 44/100 and a GF Value™ of HK$0.19 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 69 Medical Distribution companies, Sinco Pharmaceutical Holdings ranks worse than 79.71% on this metric.
Sinco Pharmaceutical Holdings Ltd stock Dividend Yield % is close to 5-year low.
The historical rank and industry rank for Sinco Pharmaceutical Holdings's Dividend Yield % or its related term are showing as below:
HKSE:06833'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.41 Med: 1.67 Max: 5.78
Current: 1.02
During the past 12 years, the highest Dividend Yield of Sinco Pharmaceutical Holdings was 5.78%. The lowest was 0.41%. And the median was 1.67%.
HKSE:06833's Dividend Yield % is ranked worse than 79.71% of 69
companies
in the Medical Distribution industry
Industry Median: 2.83
vs HKSE:06833: 1.02
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06833 vs MCK, COR, CAH: Dividend Yield % Comparison
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings Dividend Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Sinco Pharmaceutical Holdings Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
HKD 0.001670
2026-05-19
2026-05-21
2026-06-04
Cash Dividend
annually
HKD:HKD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinco Pharmaceutical Holdings (HKSE:06833) has a Dividend Yield % of 1.02% as of Aug. 28, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Sinco Pharmaceutical Holdings and its competitors. This is 39% below median its historical median of 1.67. Over the past decade, Sinco Pharmaceutical Holdings' Dividend Yield % has ranged from 0.41 to 5.78. According to the industry distribution chart, Sinco Pharmaceutical Holdings ranks #55 out of 69 companies in the Medical Distribution industry, placing it in the top 79.7%.
Is Sinco Pharmaceutical Holdings' Dividend Yield % too high?
Sinco Pharmaceutical Holdings' current Dividend Yield % of 1.02% is 39% below median its 10-year median of 1.67. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 5.78. The Medical Distribution industry median Dividend Yield % is 2.83. Sinco Pharmaceutical Holdings' value of 1.02% is 64% below this industry median. Based on the distribution chart, Sinco Pharmaceutical Holdings ranks #55 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' Dividend Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinco Pharmaceutical Holdings ranks #55 out of 69 companies for Dividend Yield %. This places Sinco Pharmaceutical Holdings in the lower half of its industry. The industry median Dividend Yield % is 2.83. Sinco Pharmaceutical Holdings' value of 1.02% is 64% below this benchmark. Historically, Sinco Pharmaceutical Holdings' own Dividend Yield % has ranged from 0.41 to 5.78 over the past decade. While the company's 10-year median is 1.67 vs. the industry median of 2.83, Sinco Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Distribution company?
The median Dividend Yield % among Medical Distribution companies is 2.83, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinco Pharmaceutical Holdings's current Dividend Yield % of 1.02% is 64% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Sinco Pharmaceutical Holdings and its competitors. For the Medical Distribution industry, the median Dividend Yield % is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinco Pharmaceutical Holdings's current Dividend Yield % is 1.02%, which is 39% below median its own 10-year median of 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current Dividend Yield % is 1.02%, which is 39% below median its 10-year median of 1.67 and 64% below the Medical Distribution industry median of 2.83. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current Dividend Yield % is 1.02% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19.
GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:06833:
Dividend Yield %: 1.02% (39% below median its 10-year median of 1.67)
GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
Industry Position: 64% below the Medical Distribution median (#55 of 69)
No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score
Get the complete analysis for HKSE:06833
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06833 has been successfully added to your 
